Abstract
PurposePathological retinal neovascularization is a clinical manifestation of various proliferative retinopathies, including retinopathy of prematurity (ROP), diabetic retinopathy, and the wet form of macular degeneration. Over the last decade, numerous studies have reported an increased infiltration of hematopoietic stem cells (HSCs), macrophage/microglia in patients with intraocular angiogenic diseases.MethodsUsing a murine model of oxygen‐induced retinopathy (OIR) and human retinal microvascular endothelial cells (HRMVECs), we are trying to understand the significance of IL‐33/Hypoxic induced VCAM1 expression in retinal neovascularization.ResultsHere, using a murine model of oxygen‐induced retinopathy, we found that NFkB and VCAM1 levels were highly up regulated in retina when new vessels were developing in the retina. Genetic deletion of IL‐33 resulted in reduced NFkB activation and VCAM1 levels in hypoxic retina, resulting in reduced neovascularization. These findings suggest a role for IL‐33‐NFkB‐VCAM1 signaling in pathological neovascularization. Our results demonstrate that IL‐33 induce tube formation in human retinal microvascular endothelial cells and depletion of VCAM1 levels significantly blocked it. Protein profiler analysis showed that IL‐33 regulates VCAM1 dependent IL‐8 expression in HRMVECs. In order, to understand how IL‐33 induced VCAM1 regulates the expression of IL‐8, we did sequence analysis of IL‐8 promoter and observed that IL‐8 promoter has AP1 binding site. We observed that IL‐33 induced the expression of Fra1 and JunB significantly in HRMVECs. Cloning and site directed mutagenesis of IL‐8 promoter revealed that the AP1 binds to IL‐8 promoter in response to IL‐33 and regulate the expression of IL‐8 in HRMVECs. Consequently, down regulation of VCAM1 levels significantly reduced IL‐33 induced Fra1 and JunB expression as well as IL‐8 expression.ConclusionsThese results strongly suggest that IL‐33/ST2L‐NFkB‐VCAM1‐AP1 regulates IL‐8 expression, playing a key role in retinal neovascularization and thus represents a new pharmacological target for the treatment of diseases where excessive neovascularization is the underlying pathology.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
